Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Multi Specific Antibodies Market: By Type, By Drug–, Bispecific ), By Indication, By End User and Geography
Multi Specific Antibodies Market: By Type, By Drug–, Bispecific ), By Indication, By End User and Geography
Multi-Specific Antibodies Market size was valued at US$ 5.6 billion in 2023 and is poised to grow at 9.5% CAGR over the forecast period from 2024 to 2030. Driven by the rising interest in R&D activities and growing need for effective medicines, the multi-specific antibody therapies market in terms of therapeutic areas, the market is expected to be driven by medications that treat cancer The rising incidence of chronic diseases, such as oncological disorders, autoimmune disorders, and infectious diseases, is expected to create demand for Multi specific antibody therapies. Such therapies offer a promising approach since they target many disease pathways at the same timeframe. Currently, two multi specific antibodies are under development to treat haematological malignancies and non-small cell lung cancer.
On March 1, 2024, Janssen Biotech, Inc., received FDA approval for amivantamab-vmjw (Rybrevant) with carboplatin and pemetrexed as a first-line treatment for locally advanced or metastatic non-small cell lung cancer. Antibody engineering has been a key driver of the multi-specific antibody business. In recent years, immense progress has been achieved in the development of novel antibody formats and engineering approaches that allow to produce Multi specific antibodies with increased efficacy and stability. For example, breakthroughs in recombinant DNA technology and protein engineering have enabled the development of bispecific antibodies with enhanced pharmacokinetics, less immunogenicity, and higher tumour penetration. The newest prospects in the Multi specific antibody market are primarily driven by increased demand for targeted and personalized medicines, as well as the advent of novel multi specific antibody formats and technologies. The increasing interest in novel Multi specific antibody formats and technology represents a significant opportunity for the multi specific antibody market.
Study Period
2024 - 2030Base Year
2023CAGR
9.5%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The Multi-Specific Antibodies Market is being driven by the ongoing discovery and expansion of therapeutic applications for multi specific antibodies (MsAbs) beyond oncology. MsAbs' versatility in treating autoimmune illnesses, infectious diseases, and other therapeutic areas expected to drive the market. Continuous advances in antibody engineering, including novel forms and superior designs, boost the therapeutic potential and efficacy of MsAbs. These technological discoveries are propelling the creation of next-generation MsAbs with increased specificity and decreased immunogenicity. Growing investment in biopharmaceutical R&D benefits the MsAbs market. Pharmaceutical corporations, investors, and research institutions provide funding to MsAbs activities, stimulating innovation and hastening their progression from preclinical to clinical applications. However, technical hurdles in MsAb development, such as establishing optimal binding affinity and stability, are a danger. Immunogenicity concerns, such as possible immunological reactions to MsAbs, may restrict their clinical efficacy and pose safety risks. The high costs and extended delays associated with MsAbs development pose a considerable challenge. High R&D costs, along with the unpredictability of clinical trial success, can be a barrier to market entry and sustainability for some companies. Additionally Stringent regulatory criteria for multi-specific antibody approval pose a concern. Delays in regulatory processes, uncertainty about data needs, and the possibility of unforeseen regulatory hurdles may delay the timely commercialization of MsAbs. The opportunity lies in the research and development of combination treatments that include MsAbs. Customizing treatment procedures and pursuing personalized medicine tactics provide opportunities to address specific patient populations while boosting treatment efficacy and Market. Therefore, Multi-Specific Antibodies Market stands to capitalize on this trend, driving continued growth and innovation within the industry.
Based on regions, the Market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. The North American area is a significant contributor to the global multi-specific antibody market. The United States (US) is the largest market for multi specific antibodies in North America, accounting for a significant portion of the global market. The country has a robust research and development infrastructure, with many biotechnology companies and university institutions focused on the development of multi-specific antibody therapies. The North American region has shown an increased interest in innovative multi-specific antibody formats and technologies, such as nanobodies and Fynomers. These new platforms enable the development of bispecific antibodies with improved pharmacokinetic and pharmacodynamic properties, resulting in more effective and customized treatments. The growing emphasis on personalized and targeted medicines is a major driver driving the multi specific antibody market in North America. This individualized approach is especially important in the case of uncommon diseases, where typical medicines may not be available or effective. The Asia-Pacific multi specific antibody market is predicted to grow significantly due to the region's large patient population. Due to poor economic conditions and lower healthcare spending, the multi-specific antibody markets in Latin America, the Middle East, and Africa are the least profitable.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024 - 2030 |
|
Market Size in 2023 |
US$ 5.6 billion |
|
Market CAGR |
9.5% |
|
By Type |
|
|
By Indication |
|
|
By End User |
|
Download Free Sample Report
Multi-Specific Antibodies Market size was valued at US$ 5.6 billion in 2023 and is poised to grow at 9.5% CAGR over the forecast period from 2024 to 2030.
The rising incidence of cancer and autoimmune illnesses is driving the market for multi specific antibodies. These diseases continue to be a large unmet medical need, and the development of new and effective treatments is critical to improve patient outcomes.
The latest trend in the multispecific antibody market is primarily driven by the growing need for targeted and personalized therapeutics, as well as the rise of novel multispecific antibody formats and technologies.
Market research is segmented based on based on type, drug, indication, end user and region.
North America is estimated to dominate with the highest CAGR over the forecast period.
| 1.Executive Summary |
| 2.Global Multi Specific Antibodies Market Introduction |
| 2.1.Global Multi Specific Antibodies Market - Taxonomy |
| 2.2.Global Multi Specific Antibodies Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Indication |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Multi Specific Antibodies Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Multi Specific Antibodies Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Multi Specific Antibodies Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Bispecific Antibody |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Tri specific Antibody |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Tetra specific Antibody |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Multi Specific Antibody |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Multi Specific Antibodies Market By Indication , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Autoimmune Disorders |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Genetic Disorders |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Haematological Malignancies |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Ophthalmic Disorders |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Skin Cancers |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Solid Tumours |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7.Global Multi Specific Antibodies Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Multi Specific Antibodies Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Multi Specific Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Bispecific Antibody |
| 9.1.2.Tri specific Antibody |
| 9.1.3.Tetra specific Antibody |
| 9.1.4.Multi Specific Antibody |
| 9.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Autoimmune Disorders |
| 9.2.2.Genetic Disorders |
| 9.2.3.Haematological Malignancies |
| 9.2.4.Ophthalmic Disorders |
| 9.2.5.Skin Cancers |
| 9.2.6.Solid Tumours |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital |
| 9.3.2.Pharmacies |
| 9.3.3.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Multi Specific Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Bispecific Antibody |
| 10.1.2.Tri specific Antibody |
| 10.1.3.Tetra specific Antibody |
| 10.1.4.Multi Specific Antibody |
| 10.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Autoimmune Disorders |
| 10.2.2.Genetic Disorders |
| 10.2.3.Haematological Malignancies |
| 10.2.4.Ophthalmic Disorders |
| 10.2.5.Skin Cancers |
| 10.2.6.Solid Tumours |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital |
| 10.3.2.Pharmacies |
| 10.3.3.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Multi Specific Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Bispecific Antibody |
| 11.1.2.Tri specific Antibody |
| 11.1.3.Tetra specific Antibody |
| 11.1.4.Multi Specific Antibody |
| 11.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Autoimmune Disorders |
| 11.2.2.Genetic Disorders |
| 11.2.3.Haematological Malignancies |
| 11.2.4.Ophthalmic Disorders |
| 11.2.5.Skin Cancers |
| 11.2.6.Solid Tumours |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital |
| 11.3.2.Pharmacies |
| 11.3.3.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Multi Specific Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Bispecific Antibody |
| 12.1.2.Tri specific Antibody |
| 12.1.3.Tetra specific Antibody |
| 12.1.4.Multi Specific Antibody |
| 12.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Autoimmune Disorders |
| 12.2.2.Genetic Disorders |
| 12.2.3.Haematological Malignancies |
| 12.2.4.Ophthalmic Disorders |
| 12.2.5.Skin Cancers |
| 12.2.6.Solid Tumours |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital |
| 12.3.2.Pharmacies |
| 12.3.3.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Multi Specific Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Bispecific Antibody |
| 13.1.2.Tri specific Antibody |
| 13.1.3.Tetra specific Antibody |
| 13.1.4.Multi Specific Antibody |
| 13.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Autoimmune Disorders |
| 13.2.2.Genetic Disorders |
| 13.2.3.Haematological Malignancies |
| 13.2.4.Ophthalmic Disorders |
| 13.2.5.Skin Cancers |
| 13.2.6.Solid Tumours |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital |
| 13.3.2.Pharmacies |
| 13.3.3.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Sonafi S.A. |
| 14.2.2.AbbVie Inc. |
| 14.2.3.Pfizer Inc. |
| 14.2.4.Johnson & Johnson |
| 14.2.5.Portola Pharmaceuticals |
| 14.2.6.Bristol-Myers Squibb |
| 14.2.7.Sino Biologics |
| 14.2.8.Roche Holding AG |
| 14.2.9.Amgen Inc. |
| 14.2.10.Novartis AG |
| 14.2.11.Merck & Co. Inc. |
| 14.2.12.Regeneron Pharmaceuticals Inc. |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.